title: Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
abstract: 'Cancer-germline' genes such as the MAGE gene family are expressed in many tumors and in male germline cells but not in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of metastatic melanoma patients. To establish whether there is a correlation between tumoral regressions and T-cell responses against the vaccine antigen, we evaluated the responses of patients vaccinated with a MAGE-3 antigenic peptide or a recombinant virus coding for the peptide. Blood lymphocytes were stimulated with antigenic peptide followed by detection with tetramer, T-cell cloning, and TCR analysis. In 4/9 regressor patients and in 1/14 progressors we found a low level, usually monoclonal cytolytic T lymphocyte response against the MAGE-3 peptide.
authors.affiliation: Cellular Genetics Unit, Institute of Cellular Pathology, Université de Louvain, Brussels, Belgium.
authors.forename: Pierre G
authors.initials: PG
authors.lastname: Coulie
authors.forename: Vaios
authors.initials: V
authors.lastname: Karanikas
authors.forename: Christophe
authors.initials: C
authors.lastname: Lurquin
authors.forename: Didier
authors.initials: D
authors.lastname: Colau
authors.forename: Thierry
authors.initials: T
authors.lastname: Connerotte
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hanagiri
authors.forename: Aline
authors.initials: A
authors.lastname: Van Pel
authors.forename: Sophie
authors.initials: S
authors.lastname: Lucas
authors.forename: Danièle
authors.initials: D
authors.lastname: Godelaine
authors.forename: Christophe
authors.initials: C
authors.lastname: Lonchay
authors.forename: Marie
authors.initials: M
authors.lastname: Marchand
authors.forename: Nicolas
authors.initials: N
authors.lastname: Van Baren
authors.forename: Thierry
authors.initials: T
authors.lastname: Boon
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D015329:Gene Rearrangement, T-Lymphocyte; D005822:Genetic Vectors / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D016233:Immunotherapy, Active; D008213:Lymphocyte Activation; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics; D012074:Remission Induction; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016896:Treatment Outcome; D014611:Vaccination; D022223:Vaccines, Subunit / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D014765:Viral Vaccines
chemical_list: C078788:ALVAC vaccine; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D016693:Receptors, Antigen, T-Cell, alpha-beta; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D014765:Viral Vaccines